Congenital myasthenic syndromes.
Congenital myasthenic syndromes (CMS) constitute a heterogenous group of inherited disorders in which neuromuscular transmission is compromised by one or more specific mechanisms. Clinical evidence for the diagnosis of a CMS includes a history of increased fatigable weakness since infancy or early childhood, a decremental EMG response, and the absence of acetylcholine receptor (AChR) antibodies. There has been rapid progress in understanding of the molecular basis of CMS. Mutation analysis of the AChR subunits has revealed numerous disease-associated mutations. These mutations alter the response to acetylcholine. It is decreased in the fast-channel syndromes and in primary AChR deficiency; and it is increased in the slow-channel syndrome due to prolonged open-time of the AChR. Acetylcholinesterase deficiency is associated with mutations in the gene encoding the collagenic tail subunit of the enzyme. Mutations in the gene encoding for choline acetyltransferase causes the CMS associated with episodic apnea.
Department of Neurology, Max Planck Institute of Psychiatry, Munich, Germany.
Joern P
JP
Sieb
Simone
S
Kraner
Ortrud K
OK
Steinlein
D000906:Antibodies / Q000276:immunology; D002795:Choline O-Acetyltransferase / Q000235:genetics / Q000378:metabolism; D004576:Electromyography; D006801:Humans; D018482:Muscle, Skeletal / Q000201:enzymology; D020294:Myasthenic Syndromes, Congenital / Q000201:enzymology / Q000235:genetics* / Q000276:immunology; D017354:Point Mutation / Q000235:genetics; D011950:Receptors, Cholinergic / Q000276:immunology / Q000378:metabolism
D000906:Antibodies; D011950:Receptors, Cholinergic; D002795:Choline O-Acetyltransferase